Teva Pharmaceutical Industries (NYSE:TEVA) and commercialization partner Celltrion announce the availability of Truxima (rituximab-abbs), a biosimilar to Roche’s (OTCQX:RHHBY) Rituxan, in the U.S.
The Wholesale Acquisition Cost (WAC) will be 10% lower than Rituxan at $845.55/100 mg vial and $4,227.75/500 mg vial. Actual costs should be lower since WAC does not account for additional rebates and discounts.
TEVA is up 4% premarket after posting Q3 results.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.